Unibest

Pharmaceutical intermediates

Linagliptin Intermediates

6 pharmaceutical intermediates for Linagliptin. Indication: Diabetes Mellitus, Type 2.

提交项目All intermediates

About Linagliptin

Originator
Boehringer Ingelheim International Gmbh
Indication
Diabetes Mellitus, Type 2
Approved Date
01/30/2015
DS/DP
05/02/2025

Available intermediates

6 intermediates currently listed for Linagliptin. Request specifications, documentation or a quotation for any item below.

Linagliptin intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Methylxanthine1076-22-8//
8-Bromo-3-methyl-3,9-dihydro-1H-purine-2,6-dione93703-24-3//
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione666816-98-4//
2-(Chloromethyl)-4-methylquinazoline109113-72-6//
8-Bromo-7-(but-2-yn-1-yl)-3-methy1-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione853029-57-9//
[(3R)-1-[7-(2-Butynyl)-2,3,6,7-tetrahydro-3-methy1-1-[(4-methy1-2-quinazolinyl)methyl]-2,6-dioxo-1H-purin-8-yll-3-piperidinyllcarbamicacid 1,1-dimethylethyl ester668273-75-4//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Linagliptin?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →